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To investigate the involvement of T-cell response against
hepatitis C virus (HCV) antigens in viral clearance after
interferon therapy, we measured interleukin-2 (IL-2) produc-
tion by peripheral mononuclear cells in response to HCV
core in patients with chronic hepatitis C. In a cohort of 43
patients, we investigated the frequency of circulating core-
specific T-helper (Th) cell precursors by the limiting-
dilution assay, and in a second cohort of 60 patients, we
analyzed the response to specific core epitopes using 52
synthetic 15-mer overlapping peptides. We observed that
the frequency of core-specific Th cell precursors was
significantly higher in patients with sustained biochemical
and virological response (SR) after interferon (IFN) therapy
(median, 1/55,736) than in untreated patients (1/274,023)
or that in patients who remained viremic after completion
of the treatment—nonresponders (NR) plus transient re-
sponders (TR) (1/1,909,972). Patients who failed to re-
spond to IFN (NR) and those who relapsed after IFN
discontinuation (TR) had a similarly low number of precur-
sors. The number of core peptides recognized by SR, TR,
NR, UT, and healthy controls was 8.2 6 1.5, 6.5 6 1.2,
2.0 6 0.5, 2.7 6 0.9, and 0.3 6 0.2, respectively. In SR, the
intensity of the proliferative response to core peptides as
estimated by the summation of stimulation indexes (SSI)
was significantly higher than in NR and than in UT, but not
different from that of TR. Our results indicate that both
expansion of HCV-specific Th cell precursors and Th cell
recognition of multiple core epitopes seem to be important
in the elimination of HCV after IFN therapy. (HEPATOLOGY
1998;28:815-822.)
Hepatitis C virus (HCV) is a small enveloped RNA virus
that is now recognized as the major agent of chronic hepatitis
and liver disease worldwide.1-3 More than 70% of those who
contract HCV develop chronic infection and hepatitis, and a
significant proportion of them progress to cirrhosis and
eventually to hepatocellular carcinoma.4,5 Interferon alfa
(IFN-a) induces normalization of serum transaminases in
30% to 40% of patients with chronic hepatitis C, but half of
them relapse after discontinuation of the therapy.6 Thus, only
around 15% to 20% of cases experience sustained biochemi-
cal and virological response to treatment.7 IFN-a has both
direct antiviral activity and immunomodulatory properties,8
and these two effects may contribute to the elimination of the
virus. However, little is known about the mechanisms that
determine that some patients respond to the therapy with
clearance of the virus and resolution of the disease, while in
others, treatment fails to eliminate the infection.
The quasispecies nature of HCV and the antigenic drift of
this virus have been proposed as mechanisms for viral
persistence.9 Chronic HCV infection occurs in the presence
of circulating antibodies against structural and nonstructural
proteins, indicating that humoral immunity is not protective
in this infection, possibly because of emergence of scape
strains within the quasispecies of the virus.9,10 Although
cellular immunity plays a critical role in the control of viral
infections, its contribution to the resolution of hepatitis C
remains to be elucidated. In particular, little is known about
whether the antiviral effect of IFN-a in patients with chronic
HCV infection may depend on the induction of an efficient
T-cell immune response against viral antigens.
T-helper (Th) cells are crucial in the orchestration of
cellular immunity against intracellular pathogens. These cells
recognize processed viral antigenic peptides bound to HLA
class II molecules on the membrane of antigen-presenting
cells. Th lymphocytes play an essential role in the activation
of cytotoxic T lymphocytes,11-13 which, in addition to mediat-
ing the elimination of virus-infected cells, participate to-
gether with Th lymphocytes in the production of cytokines
that can inhibit viral replication.14 Because T-cell help seems
to play a role in the spontaneous resolution of HCV infec-
tion,15,16 we hypothesized that Th responses might be impor-
tant for viral clearance following IFN-a therapy. Thus, we
studied Th cell reactivity against HCV core protein (a protein
highly conserved among different isolates) and core peptides
in different groups of patients with chronic hepatitis C
according to their response to IFN-a.
PATIENTS AND METHODS
Patients
For this study, we selected 80 patients with chronic HCV
infection. All of them were anti-HCV–positive and had raised
transaminase levels for more than 6 months before starting IFN-a
treatment. Patients were classified into the following groups: pa-
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tients who had not received IFN-a therapy (untreated patients
[UT]); patients with biochemical and virological response (normal
serum transaminases and negative serum HCV RNA) lasting for at
least 6 months after stopping IFN-a therapy (sustained response
[SR]); patients who failed to normalize serum transaminases during
treatment with IFN-a and remained viremic (nonresponders [NR]);
and patients with normal serum transaminases at the end of the
treatment but who relapsed after discontinuation of the therapy
(transient response [TR]). Two cohorts of patients were studied.
Cohort A: Limiting-Dilution Analysis. This cohort comprised 43
patients subdivided into three groups: 12 with sustained biochemi-
cal and virological response to IFN-a therapy, 11 patients who failed
to exibit sustained response to therapy (5 were nonresponders and 6
transient responders), and 20 untreated patients. Thus, among
treated patients, we have distinguished two main groups: those who
cleared the virus after receiving IFN-a therapy (SR) and those who
remained viremic after completion of the treatment (NR 1 TR).
Patients were studied 36.7 6 16.9 and 27.8 6 15.1 months after the
end of treatment in groups SR and NR 1 TR, respectively. A group of
6 anti-HCV–negative healthy donors (2 females and 4 males; ages 26
to 33 years; mean age, 27.8 6 2.8 years) was also included as a
control group.
Cohort B: Characterization of Immune Response Against Synthetic HCV
Core Peptides. This cohort comprised 60 patients (23 of them also
included in the first cohort) subdivided into four groups: 15 SR, 12
TR, 10 NR, and 23 UT. A group of 7 HCV-seronegative healthy
donors (2 females, 5 males; ages 27 to 55 years; mean age, 33.3 6 3.7
years) was also studied as a control group (C). Patients were investigated
7.2 6 5.4, 9.4 6 6.9, and 8.3 6 5.8 months after completion of IFN-a
treatment in groups SR, TR, and NR, respectively.
Table 1 summarizes clinical, virological, and histological charac-
teristics of the different groups of patients from the two cohorts. As
previously reported by others,17 we have found that SRs have, at
baseline, significantly lower viral load than NRs (P , .01).
Methods
Peptide Synthesis. Peptides were synthesized by the solid-phase
method of Merrifield18 using the Fmoc alternative,19 utilizing a
manual multiple solid-phase peptide synthesizer.20 The ninhydrin
test of Kaiser was used to monitor every step.21 At the end of the
synthesis, peptides were cleaved and deprotected, and washed six
times with diethyl ether. They were lyophilized and used without
further purification.
Limiting-Dilution Analysis. The limiting-dilution analysis (LDA),
used to determine frequencies of immunocompetent cells possess-
ing a defined function, requires that all conditions necessary for the
detection of a single immunocompetent cell be nonlimiting. A
positive response in a culture will then minimally depend on the
presence of a single immunocompetent cell (single-hit model).
Under our culture conditions, we assume that a single stimulated
helper T cell is able to produce enough interleukin-2 (IL-2) to
support the growing of a cell line dependent on this cytokine (CTLL
cells) at least three times over a negative control. Then, applying a
mathematical algorithm based on the Poisson probability theory, we
quantified the frequency of Th cell precursors in a population of
peripheral blood mononuclear cells (PBMC).
PBMC were isolated from fresh heparinized blood by Ficoll-
Hypaque centrifugation and washed three times with saline. Four
different concentrations of PBMC (2 3 105, 1 3 105, 5 3 104, and
2.5 3 104) were placed in 20 replica cultures (for each dilution) in
RPMI-1640 medium containing L-glutamine (2 mmol/L), gentami-
cin (10 µg/mL), penicillin (50 U/mL), streptomycin (50 µg/mL), and
HEPES (5 mmol/L), supplemented with 10% heat-inactivated hu-
man AB serum, in the presence of 1 µg/mL of recombinant HCV-core
protein genotype 1b (a generous gift from Drs. B. Rodgers and B.
Clarke, Glaxo-Wellcome, England), complemented with graded
numbers of autologous irradiated PBMC (3,000 rads) to give a total
number of 2 3 105 cells per well (96-well flat-bottomed plates). Ten
micrograms per milliliter of an anti–IL-2 receptor monoclonal
antibody (BT563, Biotest Pharma, Dreieich, Germany) was added to
the cultures according to previously described protocols.22,23 Mito-
gen stimulation of cells (positive control) was performed by
incubation with phytohaemaglutinin (PHA) (1/200 final dilution;
Gibco BRL, Grand Island, NY). After 7 days of culture at 37°C and
5% CO2, 50 µL of supernatant was harvested from cultures and
stored at 220°C. The presence of IL-2 on the supernatants was
assessed by examining the ability to support the growth of the
IL-2–dependent CTLL-2 mouse cell line. CTLL cells were resu-
pended in RPMI-1640 with 10% fetal calf serum, antibiotics, and
2-mercaptoethanol (5 3 1025 mol/L), and were plated (5 3 103 cells
per well) in a 96-well flat-bottomed plate with the supernatant to be
assayed (25% vol/vol). After 24 hours of culture, the stimulated
CTLL cells were pulsed with 1 µCi per well of [3H]thymidine for 18
hours, and thymidine incorporation was determined by liquid
scintillation (Topcount, Packard, Meridan, CT). Positive responses
TABLE 1. Clinical, Virological, and Biochemical Characteristics of Patients With Chronic Hepatitis C
Response to IFN
Cohort A Cohort B
UT NR TR SR UT NR TR SR
Number of patients 20 5 6 12 23 10 12 15
Age (yr) 35.3 6 11 50.8 6 19.5 50.8 6 14.5 44.7 6 14 53.8 6 5.1 47.5 6 3.9 40.3 6 4 39.5 6 11.1
Sex (male/female) 14/6 2/3 2/4 9/3 9/14 5/5 7/5 12/3
Viral load (3106)* 82.5 6 156 59.3 6 93.9 36.8 6 39.5 12.2 6 2.8 78.6 6 162.5 170.4 6 198.8 30.7 6 31.4 13.9 6 26.7
ALT 62.8 6 46.4 124 6 137.1 113.2 6 65.9 15.1 6 4.8 92.5 6 85.1 74.9 6 28.5 86.7 6 93.4 13.8 6 3.7
Genotype
1a 4 1 1 4 1 1
1b 10 3 6 3 14 7 10 2
2a
2b
3 4 1‡ 6 2 1 1 10
4 2† 2
nt 2 1 1 1 2
Histology cirrhosis/noncirrhosis 2/17§ 1/5 0/6 1/11 2/21 1/9 0/12 0/15
Abbreviations: nt, not tested; ALT, alanine transaminase.
*Viral load measured before IFN-a treatment.
†One of these patients was coinfected with genotype 1b.
‡Patient coinfected with genotype 4.
§Liver biopsy was available from 19 patients in group UT from cohort A.
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for the individual wells were considered when the stimulation index
(SI) (ratio of the response to HCV-core protein over mean response
in absence of protein) was above three times the negative control. Th
cell precursor frequencies were calculated on the regression curve by
interpolating the number of responder cells required to give 37%
negative cultures. The correlation coefficient was greater than 0.9 in
all cases. Only those experiments were considered for which the data
fit the single-hit model24 (evaluation according to x2).
Production of IL-2 by PBMC in Response to Synthetic HCV-Core Peptides.
PBMC were resuspended in RPMI-1640 medium supplemented with
10% heat-inactivated human AB serum and 1% antibiotics, plated at
2 3 105 cells per well, and cultured in triplicate in 96-well
flat-bottomed plates with 10 µg/mL of an anti–IL-2 receptor
monoclonal antibody (BT563, Biotest Pharma) in the presence or
absence of synthetic peptides at 25 µg/mL or PHA (1/200 final
dilution; Gibco BRL) as a positive control. After 7 days of culture,
supernatants were harvested and stored at 220°C. IL-2 production
was assessed by examining the ability to support the growth of an
IL-2–dependent CTLL mouse cell line as described above. Data are
reported as the SI, which is the ratio of mean response to peptide
over mean response to a negative control. A positive result was
considered when SI $ 5. This limit was taken to eliminate unspecific
responses (as observed in healthy controls).
Serum HCV RNA, HCV Genotypes, and Viral Load. Serum HCV RNA
was performed by the polymerase chain reaction (PCR) as previ-
ously described.25,26 Genotyping was performed using a hybridiza-
tion technique with specific probes for HCV genotypes 1a, 1b, 2a,
2b, and 3a according to Simmonds et al.,27 with the amplified HCV
core region by nested PCR as described by Viazov et al.28 with the
following technical modifications: primers for the second PCR were
58-digoxigenin–labeled, and hybridization was detected using an
anti–digoxigenine peroxidase–labeled antibody (Boehringer-Mann-
heim, Mannheim, Germany). HCV RNA was quantified by a
competitive PCR technique as previously reported.25,26
HLA Typing. HLA-DR genotyping was performed by reverse hybrid-
ization using the Standard INNO-LIPA HLA DRB kit (Innogenetics,
Ghent, Belgium). Assays were performed according to the manufac-
turer’s instructions.
Statistical Analysis. Results are presented as means 6 SEM unless
otherwise indicated. The Shapiro-Wilks normality test was used to
assess the normality of continuous data. Some variables were
logarithmically transformed for statistical analysis. For normally
distributed variables, one-way ANOVA followed by Student-Newman-
Keuls multiple comparison tests were used to analyze differences
between groups of patients. Non–normally distributed variables
were analyzed by the Kruskal-Wallis test, followed by Mann-
Whitney’s U as a multiple comparison test. Association between
continuous variables was studied with Spearman’s correlation coeffi-
cient. Fisher’s Exact test was used to analyze differences between
two percentages. Forward stepwise logistic regression analysis was
used to assess the independent association of some peptides to
sustained response to IFN-a therapy and to calculate their adjusted
odds ratios. All statistical analyses were performed with SPSS v 6.0
for Windows package. All P values were two-tailed.
RESULTS
Frequency of HCV Core-Specific Th Cell Precursors. Frequen-
cies of Th precursors recognizing HCV core protein were
calculated by LDA of PBMC from healthy controls and
HCV-infected patients. PBMC from all subjects were tested
with PHA (as a positive control of the assay), and in all cases,
a SI . 35 was obtained, indicating preserved T-cell reactivity.
The frequency of core-specific Th precursors is signifi-
cantly higher in SR (median: 1 cell in 55,736 PBMC) than in
patients who remained viremic after completion of IFN
therapy (NR 1 TR; 1/1,909,972; P , .0001) with very little
overlap between the two groups (Fig. 1). Thus, all SR
patients, except one, had precursor frequencies above 1 in
1.5 3 105 cells, while all patients who failed to exhibit
sustained response to treatment had frequencies below this
value. The abundance of circulating core-specific Th precur-
sors was similar in NR and TR (see Fig. 1), and the frequency
value in these two groups was not significantly higher than
that found in HVC-seronegative healthy controls (median:
1/650,000). UT patients exhibited a wide range of values with
a median (1/274,023) that was significantly lower than in SR
(P , .0005), but significantly higher than NR 1 TR (P ,
.05). Figure 2 shows the analysis of core-specific Th precur-
sors frequency in two representative cases, one SR and one
NR. Results are represented as a semilogarithmic plot of responder
cell input per well against the percentage of negative wells, with
the 95% confidence intervals. As can be seen in the SR case, the
percentage of negative wells decreases sharply as the number
of cells per well increases, while there is little decrease of
negative wells with increasing cell input in the NR case.
It is interesting to note that, despite the fact that SR
patients were studied 36.7 6 16.9 months after viral clear-
ance following IFN-a treatment, they exhibited strong Th
FIG. 1. Frequency of Th cell precursors (IL-2–producing cells) recogniz-
ing HCV core protein in the PBMC population from different groups of
patients with chronic hepatitis C classified according to the response to
IFN-a treatment. Calculation of the frequency of Th precursors was
performed by LDA. UT, untreated patients; NR, patients who failed to
respond to interferon; TR, transient responders, patients who showed a
complete response to IFN but relapsed upon IFN-a withdrawal; SR, patients
with sustained response to interferon. (.), correspond to TR patients.
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responses against HCV core antigen. Particularly, patient SR8
presented a very high frequency of Th cell precursors (1 per
15,126 PBMC) more than 6 years after completion of therapy.
Production of IL-2 in Response to Synthetic HCV Core Peptides.
To analyze Th response to specific HCV core protein
epitopes, we synthesized 26 15-mer overlapping peptides
(10–amino acid overlap) from conserved regions of this
protein, corresponding to genotypes 1a and 1b, as well as 26
other peptides from variable regions (Table 2). Results of IL-2
production by PBMC in response to HCV core synthetic
peptides in the different groups of patients and controls are
presented in Fig. 3. As shown, the strongest Th response
against HCV-core peptides is found in the SR group, followed
by patients with transient response to IFN-a and untreated
patients. The response is particularly poor in NR, being very
similar to that found in healthy controls (results in these
subjects are not shown). Thus, the mean number of HCV-
core peptides recognized by individuals from groups SR, TR,
UT, NR, and controls was 8.2 6 1.5, 6.5 6 1.2, 2.7 6 0.9,
2.0 6 0.5, and 0.3 6 0.2, respectively, the values in the first
three groups being significantly higher than in controls (P ,
.05). The mean number of peptides recognized by SR and TR
patients was significantly higher than in UT and NR (P ,
.05). When we calculated the SSI of peptides eliciting a
positive response (SI $ 5) in each patient from each group
(Fig. 4) as a reflection of the intensity of T-cell activation
induced by HCV core epitopes, we found that the median
value was also higher in SR and TR patients than in NR, UT,
and controls. Thus, both diversity (measured by the number
of peptides recognized) and intensity (measured by the value
of SI) of Th response appear to be associated with response to
therapy and clearance of the virus. As shown in Fig. 3, all
patients exhibited a vigorous response to PHA, indicating
that overall T-cell function was preserved in all groups.
When we analyzed the IL-2 response against individual
peptides, we observed that positive responses against pep-
tides c99-112 and c146-159 were present more frequently
among SR patients than among patients with persisting
FIG. 2. Comparison of Th cell precursors in two representative cases of
SR and NR patients using LDA. The results are shown as a semilogarithmic
plot of responder cell input per well against the percentage of negative wells.
95% confidence intervals are represented by dotted lines. (d), SR; (s), NR.
TABLE 2. Synthetic Peptides From HCV Core Protein
Peptide
Name
Position
(genotype) Sequence
Peptide
Name
Position
(genotype) Sequence
c1 1-14 (1a) MSTIPKPQRKTKRNA c27 81-94 (1a) YPWPLYGNEGCGWA
c2 1-14 (1b) MSTNPKEFRKTKRNA c28 81-94 (1b) YPWPLYGNEGMGWA
c3 6-19 (1a) KPQRKTKRNTNRRPA c29 85-98 (1a) LYGNEGCGWAGWLLA
c4 6-19 (1b) KEFRKTKRNTLRRPA c30 85-98 (1b) LYGNEGMGWAGWLLA
c5 11-24 (1a) TKRNTNRRPQDVKFA c31 90-103 (1a) GCGWAGWLLSPRGSA
c6 11-24 (1b) TKRNTLRRPQDVRFA c32 90-103 (1b) GMGWAGWLLSPRGSA
c7 15-28 (1a) TNRRPQDVKFPGGGA c33 95-108 GWLLSPRGSRPSWGA
c8 15-28 (1b) T LRRPQDVRFPGGGA c34 99-112 SPRGSRPSWGPTDPA
c9 20-33 (1a) QDVKFPGGGQIVGGA c35 104-117 RPSWGPTDPRRRSRA
c10 20-33 (1b) QDVRFPGGGQIVGGA c36 109-122 PTDPRRRSRNLGKVA
c11 25-38 PGGGQIVGGVYLLPA c37 113-126 RRRSRNLGKVIDTLA
c12 29-42 QIVGGVYLLPRRGPA c38 118-131 NLGKVIDTLTCGFA
c13 34-47 VYLLPRRGPRLGVRA c39 123-136 IDTLTCGFADLMGYA
c14 39-52 RRGPRLGVRATRKTA c40 127-140 TCGFADLMGYIPLVA
c15 43-56 RLGVRATRKTSERSA c41 132-145 DLMGYIPLVGAPLGA
c16 48-61 ATRKTSERSQPRGRA c42 137-150 IPLVGAPLGGAARA
c17 53-66 SERSQPRGRRQPIPA c43 141-154 GAPLGGAARALAHGA
c18 57-70 (1a) QPRGRRQPIPKVRRA c44 146-159 GAARALAHGVRVLEA
c19 57-70 (1b) QPRGRRQPIPKARQA c45 151-164 LAHGVRVLEDGVNYA
c20 62-75 (1a) RQPIPKVRRPEGRTA c46 155-168 VRVLEDGVNYATGNA
c21 62-75 (1b) RQPIPKARQPEGRA c47 160-173 DGVNYATGNLPGCSA
c22 67-80 (1a) KVRRPEGRTWAQPGA c48 165-178 ATGNLPGCSFSIFLA
c23 67-80 (1b) KARQPEGRAWAQPGA c49 169-182 LPGCSFSIFLLALLA
c24 71-84 (1a) PEGRTWAQPGYPWPA c50 173-186 SFSIFLLALLSCLTA
c25 71-84 (1b) PEGRAWAQPGYPWPA c51 178-191 (1a) LLALLSCLTVPASA
c26 76-89 WAQPGYPWPLYGNEA c52 178-191 (1b) LLALLSCLTIPASA
*The underlined Alanine was added to peptides for synthesis convenience. The amino acids differing in sequences 1a and 1b are indicated in bold in
genotype 1b peptides.
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FIG. 3. IL-2 production in response to HCV core peptides by PBMC from patients with chronic hepatitis C and controls. Rows correspond to patients, and
columns correspond to peptides. Results are presented as the SI (mean cpm with peptide/mean cpm without peptide). Higher SI are indicated with darker
shades of gray. The recognition of peptides from conserved areas is indicated by a full square, while recognition of peptides from variable regions (peptides in
bold) is indicated in two halves: the upper part of each square corresponds to sequence 1a, and the lower part corresponds to sequence 1b. The response of each
patient to PHA is also indicated. HCV genotypes are specified on the right side of the figure.
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viremia after completion of IFN-a treatment (9 of 15 SR vs. 1
of 22 NR 1 TR responded to c99-112, and 9 of 15 SR vs. 3 of
22 NR 1 TR responded to c146-159). Using a logistic
regression model, peptides c99-112 and c146-159 were found
to be independently associated with sustained response to
interferon (P , .005 and P , .01, respectively), with adjusted
odds ratios of 42.1 (95% CI: 3.4-526.5) and 13.2 (95% CI:
1.7-100.5), respectively. Response to at least one of these two
peptides was observed in 12 of 15 (80%) patients with
sustained response, but only in 4 of 22 (18.1%) patients who
remained viremic after completing IFN-a treatment (TR 1
NR) (P 5 .0001; combined odds ratio: 31.7; 95% CI:
4.5-221.7). Analysis of HLA-DR molecules did not reveal any
association between the response to these peptides and the
presence of specific HLA-DR molecules in the groups of
patients studied (data not shown). Thus, peptides c99-112
and c146-159 induced positive IL-2 response in patients with
different HLA-DR molecules, suggesting that these peptides
are recognized in the context of different HLA-DR alleles.
We observed that PBMC from patients infected with viral
genotypes other than 1a and 1b were able to produce
detectable amounts of IL-2 when stimulated with core
peptides from sequences 1a and 1b. This can be clearly seen
in the SR group, in which most of the patients were infected
with genotype 3a (Fig. 3).
Viral Load and Core-Specific Th Precursors. In cohort A,
viremia was quantified in the same sample used for immuno-
logical studies. When all viremic patients were included, no
relationship was found between Th precursor frequency and
viral load (Fig. 5A). However, when only patients with low
viremia (below 1 3 107 copies per milliliter; n 5 7) were
considered, a close inverse correlation emerged between
precursor frequency and viral load (r 5 .89; P 5 .007)
(Fig. 5B).
DISCUSSION
In chronic hepatitis C, the contribution of specific T-cell
immunity to the resolution of HCV infection following IFN-a
therapy has not yet been clarified. The present article is
intended to provide information on this point.
Our results show that patients manifesting sustained
biochemical and virological response to interferon (SR group)
possess a number of core-specific Th precursors 34 times
higher than those who fail to clear HCV (NR 1 TR). It was of
interest that NR and TR, despite being in contact with the
virus for many years, have a Th precursor frequency similar
to that of healthy HCV-seronegative controls. The situation
was different in untreated patients; these subjects present a
wide range of core-specific Th precursor frequencies, with a
median value that was significantly lower than that of SR, but
significantly higher than NR 1 TR. Longitudinal studies are
needed to evaluate the changes in Th precursor frequency
FIG. 4. Median value of SSI obtained with peptides eliciting positive Th
response (SI $ 5) in patients from each group. C, healthy controls. **P ,
.001 vs. C; P , .01 vs. NR; P , .05 vs. UT; *P , .05 vs. C.
FIG. 5. Relationship between viral load and frequency of Th cell
precursors against core in all viremic patients from cohort A (UT and NR
after IFN therapy; n 5 25) (A) and in those patients with low viremia (below
1 3 107 copies per milliliter; n 5 7/25) (B).
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that occur during IFN-a therapy and the relationship be-
tween these changes and the ultimate treatment outcome.
In addition to these findings, we observed that the number
of core peptides recognized by Th increased progressively in
NR, UT, TR, and SR (from 2.0 6 0.5 in NR to 8.2 6 1.5 in
SR), and that the intensity of the Th response against core
peptides (as estimated by SI) was higher in SR than in UT or
NR. Thus, our data indicate that sustained response to IFN-a
is associated with both an expanded number of Th cell
precursors against HCV core antigen and an extensive
recognition of HCV core epitopes. In contrast, failure to clear
the virus is associated with a low precursor frequency,
comparable with that found in subjects without previous
contact with the virus.
Our results are in accordance with reports from other
authors,16,29-31 indicating that Th responses to different viral
antigens (including core) were associated with a benign
course of HCV infection. Along the same lines, Sarobe et al.23
found that the response to synthetic peptides from HCV-E1
protein was higher (in terms of number of peptides recog-
nized and value of the SI) in those patients who resolved the
infection after IFN-a therapy than in those who failed to clear
the virus. Hoffman et al.32 also observed that CD41 lympho-
cyte response against HCV proteins was more common in
patients who responded to therapy than in nonresponders,
and Iwata et al. 33 demonstrated a greater production of IFN-g
in response to core in patients who eliminated HCV infection
after IFN-a treatment, further emphasizing the role of Th
cells in IFN-induced HCV clearance.
The wide range of determinants recognized by T cells in SR
patients (Fig. 3) may be important in the prevention of the
appearance of escape mutants, thus facilitating the elimina-
tion of the infection. It is of interest to note that SR patients
recognized peptides from genotypes 1a and 1b, despite the
fact that many of them were infected with genotype 3. This
finding indicates a high degree of cross-reactivity between
peptides of different genotypes in this highly conserved viral
protein.34 Similar results, showing cross-reactivities between
peptides from different genotypes have been reported by
others.
16, 35
In addition to quantitative aspects, the specificity of the Th
response may also play a role in the elimination of the
infection. Recently, Diepolder et al.36 identified a peptide
from NS3 protein (amino acids 1248 to 1261), associated
with viral clearance in self-limited acute infection, that can be
presented to CD41 cells by a great number of HLA-DR alleles.
Similarly, Lechmann et al.,37 using HCV-core 25-mer pep-
tides, observed an association between the proliferative
response to peptide CT4 (amino acids 148-172) and viral
clearance. Using shorter synthetic peptides, we found that
peptides c146-159 (encompassed by CT4) and c99-112, both
corresponding to highly conserved regions,34 showed an
association with resolution of the infection after IFN-a
therapy. Although the number of patients is not high enough
to draw solid conclusions, the peptides described here may
deserve consideration in the design of future T-cell–targeted
immunotherapies for HCV infection.
As mentioned, vigorous Th anti-core reactivity was found
in SR even years after completion of the therapy. This finding
is in agreement with results from Ferrari et al.,38 who showed
that asymptomatic anti-HCV–positive subjects who success-
fully cleared HCV RNA after a previous episode of acute HCV
infection express strong T-cell responses to HCV antigens
years after resolution of hepatitis. In hepatitis B virus
infection, it has been postulated that sterilizing immunity
frequently fails to occur after recovery from acute hepatitis,
and that traces of virus can maintain an activated immune
response for decades following clinical recovery, keeping the
virus under control.39 This could also be the situation in HCV
infection after viral clearance following IFN-a therapy.
Finally, it should be mentioned that no clear relationship
exists between viral load and the frequency of Th precursors
when all viremic patients are considered. However, a close
inverse relationship was found when only patients with
viremia below 1 3 107 copies per milliliter were considered.
Although the analysis in this subgroup of 7 patients might be
artificial, one could speculate that Th response is effective
only in controlling low levels of viral replication. A similar
result has been found by Rehermann et al.35 and by Hiroishi
et al.40 when they studied cytotoxic T lymphocyte responses
in patients with chronic HCV infection. In this context,
IFN-a might act simultaneously by reducing viremia and by
stimulating a T-cell immune response that might be effective
only in the setting of low viral replication.
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